Acute Liver Failure, Cirrhosis & Hepatic Drug Effects

Distinguish Two Different Hepatic Syndromes

Acute liver failure (ALF) is a rapidly evolving syndrome with hepatic dysfunction, coagulopathy, and encephalopathy in a patient without established cirrhosis in the usual definition. Acute decompensation of cirrhosis occurs on a background of chronic liver disease and may involve infection, bleeding, ascites, kidney dysfunction, and encephalopathy. Both need urgent care, but cerebral edema is a particularly important threat in advanced ALF. Do not transfer a familiar cirrhosis treatment routine to ALF without assessing this difference.

The official blueprint includes fulminant liver failure, brain edema, cirrhosis decompensation, and altered hepatic drug clearance. Initial priorities are systemic stability, glucose, airway protection, cause identification, and early hepatology or transplant consultation. A patient who is deteriorating neurologically should be discussed with a transplant-capable center before the need for transfer becomes a last-minute emergency.

Etiology and Initial Assessment

Consider acetaminophen toxicity, other drugs or supplements, viral hepatitis, autoimmune disease, ischemic injury, and pregnancy-related disease as appropriate. Obtain a careful exposure history and relevant tests; a negative late acetaminophen level does not necessarily exclude preceding toxicity. N-acetylcysteine is central to acetaminophen-associated failure and may be used in selected non-acetaminophen ALF under specialist guidance. Treatment of a suspected toxic exposure should not wait unnecessarily for a perfect history.

Assess glucose repeatedly because impaired hepatic production can cause recurrent hypoglycemia. Evaluate acid–base status, lactate, electrolytes, kidney function, infection, coagulation, and cardiovascular function. Liver enzymes reflect injury and are not a direct measure of recovery; falling aminotransferases can coexist with worsening liver failure if functioning cell mass is being lost. Interpret trends with INR, bilirubin, glucose, perfusion, and encephalopathy.

Cerebral Edema and Intracranial Hypertension

Hyperammonemia contributes to astrocytic glutamine accumulation and swelling. Inflammation, altered cerebral blood flow, and systemic organ dysfunction also contribute. As encephalopathy advances, patients can lose airway protection, develop seizures, and suffer intracranial hypertension. Avoid hypoxemia, hypotension, fever, hyponatremia, and unnecessary stimulation while arranging definitive hepatic care.

ICP monitoring is selective, not routine for every patient with ALF. Potential benefit must be balanced against bleeding risk and whether the information will change management. CT may exclude another structural cause but can be insensitive to early edema. Serial examination and physiologic assessment remain important even when a scan is initially reassuring.

Selected patients receive a carefully monitored sodium strategy and renal replacement to control ammonia and fluid balance. The appropriate prescription depends on the clinical situation. Mannitol or hypertonic saline may treat intracranial crises but does not cure liver failure or replace transplant assessment. Avoid prolonged prophylactic hyperventilation; brief rescue hypocapnia may be used during herniation while definitive measures are organized.

Cirrhosis-Associated Encephalopathy

In established cirrhosis, seek precipitating infection, GI bleeding, constipation, dehydration, electrolyte problems, kidney failure, or sedating medication. Hepatic encephalopathy is a clinical diagnosis after considering alternatives. Asterixis, altered attention, and sleep-wake changes are useful clues but are not specific. A high ammonia concentration alone cannot establish that every symptom is hepatic, and a discordant result should prompt reassessment.

Lactulose is commonly used to reduce intestinal nitrogen absorption; titrate to an appropriate stool response while avoiding severe diarrhea, dehydration, or electrolyte loss. Rifaximin is used in selected settings, including recurrence prevention. Treat the precipitant. These approaches to cirrhosis should not be represented as proven definitive treatment of ALF cerebral edema. A patient with infection-related deterioration may need antimicrobial therapy and source control in addition to bowel-directed treatment.

Coagulation and Medication Interpretation

A high INR in liver disease does not measure the entire balance between bleeding and thrombosis. Platelet, coagulation-factor, anticoagulant-protein, and fibrinolytic changes coexist. Procedures and active bleeding require individualized assessment; automatically correcting every abnormal INR with large plasma volumes can cause harm and obscure prognostic trends. Use hepatology, procedural, and transfusion guidance for the actual indication.

Hepatic dysfunction can reduce metabolism of sedatives and analgesics; low albumin changes free drug fractions. Renal failure can further alter clearance of active metabolites. Use the smallest effective exposure, reassess frequently, and consider a free antiseizure-drug level when a total level is misleading. Improvement in a liver laboratory value does not instantly remove accumulated medication.

In a vignette, a patient with cirrhosis becomes obtunded after a GI bleed and several sedative doses. The appropriate response is to stabilize bleeding and perfusion, investigate precipitants and drug accumulation, check glucose and electrolytes, and evaluate seizures or structural disease when indicated. Simply escalating lactulose without reassessing these competing threats is incomplete care.

Source checked October 17, 2026: AASLD acute liver failure guidance. Its longstanding principles are supplemented by the patient's transplant-center protocol and current specialist assessment.